These agents limit tumor growth by inhibiting angiogenesis; they include TKI (i.e. axitinib, cabozantinib, sunitinib), monoclonal antibodies targeting either soluble VEGF or VEGF receptors (i.e. bevacizumab, ramucirumab), and decoy receptors known as VEGF-Traps that impede soluble VEGF from binding to its receptors (Aflibercept) [52]. Here, VEGFA is linked to neoplasm.